Reinventing Medicine

with Protein Degradation

Our Company

Expanding the Range of
Treatable Disease

Kymera is committed to advancing cutting-edge science to develop a new generation of medicines that address critical health problems and dramatically improve patients’ lives by targeting the fundamental drivers of disease.

Redefining New Treatment Paradigms

Targeted protein degradation is a disease-agnostic modality fundamentally changing how drugs can work, creating unprecedented opportunities to treat a wide variety of diseases.

Our Company

Our team is committed to delivering life-changing medicines with passion, focus, and a sense of urgency.

Our Pipeline

Driven by our powerful and highly productive drug discovery engine, we are delivering a pipeline of first-in-class therapeutics designed to transform the standard of care for patients.

Recent News
December 13, 2023
Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4
December 10, 2023
Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting
December 7, 2023
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi
Our Team

Kymera is building a fully integrated medicines company to redefine disease treatment. Learn more about how you can help shape the future of medicine.